265
Participants
Start Date
July 26, 2023
Primary Completion Date
July 31, 2026
Study Completion Date
January 31, 2028
Everolimus 10 mg
Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
CDK4/6 Inhibitor SHR6390
Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER